SPRY

Over the past six months, ARS Pharmaceuticals' stock has experienced volatility. Key events include regulatory approvals and updates, such as the FDA approving updated prescribing information for neffy® and Health Canada granting approval for neffy®. The company reported its Q4 2025 financial results, beating EPS and revenue forecasts, but concerns were raised about the slow commercial uptake of neffy®. Analyst coverage includes Northland initiating coverage with an "Outperform" rating and Leerink Partners raising its price target. The stock has shown volatility, correlating with FDA communications, and has underperformed due to weak refill rates, payer friction, and high cash burn.